This listing of claims will replace all prior versions and listings of claims in the application.

Listing of the Claims

Claims 1-48 (canceled)

49. (new) An inclusion complex of a modafinil compound and a cyclodextrin wherein the modafinil compound has an aqueous solubility of at least 10 mg/ml.

50. (new) The inclusion complex of claim 1 wherein the molar ratio of cyclodextrin to the modafinil compound is from about 10:1 to about 0.8:1.

51. (new) The inclusion complex of claims 1 or 2 wherein the cyclodextrin is α-cyclodextrin, β-cyclodextrin, γ-cyclodextrin, dimethyl-β-cyclodextrin, trimethyl-β-cyclodextrin, 2-hydroxymethyl-β-cyclodextrin, 2-hydroxypropyl-β-cyclodextrin, 3-hydroxypropyl-β-cyclodextrin, β-cyclodextrin sulfate, β-cyclodextrin sulfonate, or β-cyclodextrin sulfobutyl ether.

52. (new) The inclusion complex of claim 3 wherein the modafinil compound is modafinil and the cyclodextrin is a β-cyclodextrin.

53. (new) The complex of claim 4 wherein the modafinil compound is the levorotatory form of modafinil.

54. (new) The complex of claim 54 wherein the cyclodextrin is 2-hydroxypropyl-β-cyclodextrin.

55. (new) The complex of claim 2 wherein the molar ratio of cyclodextrin to the modafinil compound is about 4:1.

56. (new) The complex of claim 7 wherein the molar ratio of cyclodextrin to the modafinil compound is about 1:1.

57. (new) The complex of claim 1 wherein the modafinil compound has an aqueous solubility of at least 20 mg/ml.

58. (new) A pharmaceutical composition comprising an inclusion complex of a modafinil compound and a cyclodextrin wherein the modafinil compound has an aqueous solubility of at least 10 mg/ml.

59. (new) The composition of claim 10 wherein the modafinil compound has an aqueous solubility of at least 20 mg/ml.

60. (new) The composition of claim 10 wherein the molar ratio of cyclodextrin to the modafinil compound is from about 10:1 to about 0.8:1.

61. (new) The composition of claim 12 wherein the molar ratio of cyclodextrin to the modafinil compound is about 4:1.

62. (new) The composition of claim 13 wherein the molar ratio of cyclodextrin to the modafinil compound is about 1:1.

63. (new) The composition of claim 10 wherein the composition provides at least a 25% increase in the blood serum level upon oral administration of a modafinil compound to a mammal relative to a solid dose of modafinil compound.

64. (new) The composition of claim 15 wherein the composition provides at least a 50% increase in the blood serum level of a modafinil compound in a mammal within the first hour of administration relative to a solid dose of a modafinil compound.

65. (new) The compositions of claims 15 or 16 wherein the composition is in a solution form.

66. (new) The composition of claim 10 wherein the cyclodextrin is α-cyclodextrin, β-cyclodextrin, γ-cyclodextrin, dimethyl-β-cyclodextrin, trimethyl-β-cyclodextrin, 2-hydroxymethyl-β-cyclodextrin, 2-hydroxypropyl-β-cyclodextrin, 3-hydroxypropyl-β-cyclodextrin, β-cyclodextrin sulfate, β-cyclodextrin sulfonate, or β-cyclodextrin sulfobutyl ether.

67. (new) The composition of claim 18 wherein the modafinil compound is modafinil and the cyclodextrin is a β-cyclodextrin.

68. (new) The composition of claim 19 wherein the modafinil compound is the levorotatory form of modafinil.

69. (new) The composition of claim 20 wherein the cyclodextrin 2-hydroxypropyl-β-cyclodextrin.

70. (new) The composition of claim 20 wherein the composition comprises modafinil in an aqueous 50% 2-hydroxypropyl-β-cyclodextrin solution.

71. (new) The composition of claim 10 which has substantially the blood serum profile of FIG. 1.

72. (new) The composition of claim 10 wherein the composition is in a solution form.

73. (new) The composition of claim 24 wherein the composition is aqueous and suitable for oral consumption.

74. (new) The composition of claim 24 wherein the composition is a syrup or elixir.

75. (new) The composition of claim 10 wherein the composition is in a solid form.

76. (new) The composition of claim 27 wherein the composition is in the form of a tablet or a capsule.

77. (new) The composition of claim 10 comprising one or more unit doses of modafinil.

78. (new) The composition of claim 29 comprising one unit dose of modafinil.

79. (new) The composition of claim 30 wherein the unit dose is 200 mg of modafinil.

80. (new) The composition of claim 30 wherein the unit dose is 100 mg of modafinil.

81. (new) The composition of claim 10, 19, or 20 wherein the modafinil compound is taste-masked.

82. (new) The composition of claim 33 wherein the composition is a syrup or elixir.

83. (new) A method of preparing an inclusion complex of a modafinil compound and a cyclodextrin wherein the modafinil compound has an aqueous solubility of at least 10 mg/ml comprising contacting the modafinil compound with the cyclodextrin in an aqueous medium.

84. (new) The method of claim 35 wherein the inclusion complex is dried and isolated as a solid.

85. (new) A method of treating a disease or disorder in a subject, comprising administering a therapeutically effective amount of a composition of a

modafinil compound and a cyclodextrin to a subject.

86. (new) The method of claim 37 wherein the composition is administered for the treatment of sleepiness, tiredness, Parkinson's disease, cerebral ischemia, stroke, sleep apneas, eating disorders, attention deficit hyperactivity disorder, cognitive dysfunction or fatigue; and for the promotion of wakefulness, stimulation of appetite, or stimulation of weight gain.

87. (new) The method of claim 38 wherein the composition is administered orally.